Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al.|Nature Medicine|2004Cited by 2k
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Dan G. Duda, Emmanuelle di Tomaso et al.|Journal of Clinical Oncology|2009Cited by 507
Imaging amyloid deposition in Lewy body diseasesStephen N. Gomperts, Keith A. Johnson, Bradley T. Hyman et al.|Neurology|2008Cited by 446
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419
Farnesyltransferase Inhibitor FTI-277 Reduces Mortality of Septic Mice along with Improved Bacterial ClearanceWen Yang, Masao Kaneki, Marina Yamada et al.|Journal of Pharmacology and Experimental Therapeutics|2011Cited by 26